Skip to Main Content

Let’s list the good news that emerged Tuesday night from Gilead Sciences’ (GILD) first-quarter earnings report: Sales of the personalized cellular cancer therapy Yescarta totaled $40 million, nicely above the $18 million consensus forecast.

And that’s it.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.